Understanding how Eltrombopag helps with aplastic anemia
Eltombopag: Novel Mode of Action on Normal and Aplastic Anemia Hematopoietic Stem Cells
This research explores how the medication Eltrombopag helps patients with aplastic anemia by looking at its effects on blood-forming cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11120856 on NIH RePORTER |
What this research studies
Aplastic anemia is a serious condition where the body's immune system attacks its own blood-forming cells, leading to low blood counts. While some treatments help, many patients still struggle. A medication called Eltrombopag has shown great promise, not just by increasing platelets but also by helping the body make other types of blood cells. This project aims to uncover the exact ways Eltrombopag works, especially how it helps blood-forming cells grow and recover, even beyond its known effects. We believe understanding these mechanisms could lead to better ways to use this drug and develop new treatments.
Who could benefit from this research
Good fit: Patients with aplastic anemia, particularly those who have received or are considering Eltrombopag, might find this research relevant to their condition.
Not a fit: Patients without aplastic anemia or related blood disorders would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to a deeper understanding of Eltrombopag's effects, potentially improving treatment strategies and outcomes for patients with aplastic anemia.
How similar studies have performed: Eltrombopag is already a successful treatment for aplastic anemia, but this research explores a new, previously unknown mechanism of its action.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Lerner Com-Cwru — Cleveland, United States (Active)
Researchers
- Principal investigator: Maciejewski, Jaroslaw P. — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Maciejewski, Jaroslaw P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.